miRNA-21表达水平与结直肠癌患者预后关系的Meta分析  

The prognostic value of miRNA-21 expression in patients with colorectal cancer:a Meta-analysis

作　　者：王斌[1] 姜雷[2] 王冰冰[1] 王斌贤 于小源[1] 王亨强 王盼盼[1] 

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730000 [2]兰州大学第一医院肿瘤外科,甘肃兰州730000

出　　处：《肿瘤》2015年第1期84-91,共8页Tumor

基　　金：甘肃省自然科学基金资助项目(编号:145RJZA229)~~

摘　　要：目的：应用Meta分析评价微RNA-21（micro RNA-21,miR-21）表达与结直肠癌患者预后的关系。方法：利用计算机检索Pub Med、EMBase、中国知网（National Knowledge Infrastructure,CNKI）、万方数据资源系统（Wanfang Database）和中国生物医学文献数据库（Chinese Biomedical Literature Database）从建库至2014年7月公开发表的文献,对符合纳入标准的文献,提取基本信息,并进行方法学质量评价。选用Rev Man 5.3和Stata 12.0软件对所有的数据进行Meta分析。结果：最终纳入9篇文献,共1 671个病例。所有结直肠癌患者总生存期风险比（hazard ratio,HR）的合并值为1.83[95%可信区间（coni dence interval,CI）为1.37～2.43,P〈0.000 1）;剔除异质性研究后,HR的合并值为2.57（95%CI为2.06～3.21,P〈0.000 01）。结论：miR-21的高表达与结直肠癌的不良预后有一定的关系。Objective：To quantitatively assess the prognostic value of microRNA-21（miR-21） expression in colorectal cancer patients using Meta-analysis in order to provide advanced evidence for clinical decision making.Methods：The PubMed,EMBase,National Knowledge Infrastructure database,Wanfang Datebase and Chinese Biomedical Literature Database were searched from their inception to July,2014.The basic information was extracted and the methodological quality of the included studies was assessed.The RevMan 5.3 software and Stata1 2.0 software were used for Meta-analysis.Results：Nine studies（a total of 1 671 patients） were included in the present Meta-analysis.The analysis results indicated that up-regulation of miR-21 expression predicted poor overall survival（OS）,with a pooled hazard ratio（HR） of 1.83[95%confidence interval（CI）：1.37-2.43,P〈0.000 1].After eliminating the studies with heterogeneity,the higher expression of miR-21 was significantly related to poor OS in patients with colorectal cancer（pooled HR =2.57,95%CI：2.06-3.21,P〈0.000 01）.Conclusion：The findings from this Meta-analysis suggest that the elevated miR-21 expression is associated with poor prognosis in patients with colorectal cancer.

关 键 词：结直肠肿瘤 微RNAS 预后 META分析 

分 类 号：R737.9[医药卫生—肿瘤]